5,834 reports of this reaction
3.1% of all FLUTICASONE PROPIONATE reports
#4 most reported adverse reaction
DYSPNOEA is the #4 most commonly reported adverse reaction for FLUTICASONE PROPIONATE, manufactured by Haleon US Holdings LLC. There are 5,834 FDA adverse event reports linking FLUTICASONE PROPIONATE to DYSPNOEA. This represents approximately 3.1% of all 187,924 adverse event reports for this drug.
Patients taking FLUTICASONE PROPIONATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among FLUTICASONE PROPIONATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for FLUTICASONE PROPIONATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 5,834 FDA reports for FLUTICASONE PROPIONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.1% of all adverse event reports for FLUTICASONE PROPIONATE, making it a notable side effect.
If you experience dyspnoea while taking FLUTICASONE PROPIONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.